Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis
Abstract Introduction Evidence for dual antidiabetic therapy in type 2 diabetes mellitus patients with cirrhosis is limited. This study compared 5-year mortality, composite hepatic decompensation risk, and hepatocellular carcinoma occurrence in patients with diabetes and cirrhosis who were either on...
Main Authors: | Daniel J Huynh, Benjamin D Renelus, Daniel S Jamorabo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-12-01
|
Series: | BMC Gastroenterology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12876-023-03085-8 |
Similar Items
-
The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review
by: Yasunori Miyamoto, et al.
Published: (2023-03-01) -
Hepatic Hydrothorax—An Independent Decompensating Event Associated with Long-Term Mortality in Patients with Cirrhosis
by: Daniela Matei, et al.
Published: (2021-08-01) -
Evaluation of five lymphocyte-based scores for prediction of mortality in hepatitis B virus-associated decompensated cirrhosis
by: Ting Mao, et al.
Published: (2023-08-01) -
Severe anemia is associated with increased short-term and long-term mortality in patients hospitalized with cirrhosis
by: Haotang Ren, et al.
Published: (2023-11-01) -
Liver-related long-term outcomes of alpha-glucosidase inhibitors in patients with diabetes and liver cirrhosis
by: Fu-Shun Yen, et al.
Published: (2022-12-01)